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A673V mutationAlthough Alzheimer's disease (AD) is usually sporadic, in a small proportion of cases it is familial and can be
linked to mutations in β-amyloid precursor protein (APP). Unlike the other genetic defects, the mutation
[alanine-673→valine-673] (A673V) causes the disease only in the homozygous condition with enhanced
amyloid β (Aβ) production and aggregation; heterozygous carriers remain unaffected. It is not clear how
misfolding and aggregation of Aβ is affected in vivo by this mutation and whether this correlates with its toxic
effects. No animal models over-expressing the A673V–APP gene or alanine-2-valine (A2V) mutated human Aβ
protein are currently available. Using the invertebrate Caenorhabditis elegans, we generated the ﬁrst transgenic
animal model to express the human Aβ1–40 wild-type (WT) in neurons or possess the A2V mutation
(Aβ1–40A2V). Insertion of an Aβ-mutated gene into this nematode reproduced the homozygous state of
the human pathology. Functional and biochemical characteristics found in the A2V strain were compared
to those of transgenic C. elegans expressing Aβ1–40WT. The expression of bothWT and A2V Aβ1–40 speciﬁcally
reduced the nematode's lifespan, causing behavioral defects and neurotransmission impairment which
were worse in A2V worms. Mutant animals were more resistant than WT to paralysis induced by the
cholinergic agonist levamisole, indicating that the locomotor defect was speciﬁcally linked to postsynaptic
dysfunctions. The toxicity caused by the mutated protein was associated with a high propensity to form
oligomeric assemblies which accumulate in the neurons, suggesting this to be the central event involved
in the postsynaptic damage and early onset of the disease in homozygous human A673V carriers.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license. Introduction
Alzheimer's disease (AD) is a chronic neurodegenerative disorder
and one of the leading causes of death among the elderly in western
countries (Hardy and Selkoe, 2002; Holtzman et al., 2011).
AD is usually sporadic, but a small proportion of cases are familial.
Neuropathological hallmarks of familial AD are the same as in sporadic
forms (Bertram and Tanzi, 2005). However, familial cases usually have
an earlier age of onset and show an autosomal-dominant pattern ofede).
ect.com).
. Open access under CC BY-NC-SA liceninheritance with virtually complete penetrance linked to mutations in
theβ-amyloid precursor protein (APP) or presenilins genes. Genetic de-
fects may result in overproduction of amyloid β (Aβ) or in the genera-
tion of mutated Aβ forms with a greater propensity for aggregation
(Rocchi et al., 2003).
Recently we identiﬁed a novel human APP mutation at codon 673
(A673V) in the N-terminal part of the Aβ sequence at position 2. Unlike
the other genetic defects inducing AD, this mutation only has a patho-
genic role in the homozygous condition (Di Fede et al., 2009). The neu-
ropathological picture of the recently deceased A673V homozygous
proband of this family revealed hallmarks consistent with degenerative
dementia of AD type but also showed several distinct characteristics
compared with sporadic or familial AD inherited as a dominant trait
(Giaccone et al., 2010). The major speciﬁc features are the morphology,
structural properties, topographic distribution and composition of Aβ
deposits (Giaccone et al., 2010).se. 
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in cells transiently transfected with mutant or wild-type (WT) APP
cDNA, indicated that the insertion of the A673V mutation promoted a
shift in APP processing towards the amyloidogenic pathway, resulting
in enhanced Aβ production (Di Fede et al., 2009). In vitro investigations
indicated that the alanine-2-valine (A2V) substitution in Aβ synthetic
peptides increased their aggregation propensity and cellular neurotoxic-
ity compared with WT (Di Fede et al., 2012). The insertion of the A2V
mutation into the Aβ1–40 peptide increased its in vitro propensity to
form soluble oligomeric specieswhich act as “stressors” inCaenorhabditis
elegans, signiﬁcantly inhibiting pharyngeal pumping (Beeg et al., 2013;
Stravalaci et al., 2012). In addition, interaction between the A2V mutant
and WT peptides hindered in vitro amyloidogenesis and Aβ-mediated
neurotoxicity, accounting for the absence of disease in the A673Vhetero-
zygous carriers (Di Fede et al., 2009, 2012).
It is important to clarify howmisfolding and aggregation patterns of
Aβ are affected by mutation and whether this correlates with disease
onset and progression. An animal model over-expressing the A673V-
APP gene or A2V mutated human Aβ protein could help unveil the
mechanisms underlying themarked pathogenic effects of thismutation.
Using the invertebrate C. elegans, we generated the ﬁrst transgenic an-
imal to express human Aβ1–40 carrying the A2V mutation (Aβ1–40A2V) in
neurons. This peptide was selected on the basis of neuropathological
observations of the homozygous proband where the deposition of Aβ40
species was over-represented and the effects of the A673V genetic muta-
tion were more pronounced on Aβ40 than on Aβ42 (Giaccone et al.,
2010). Since this nematode naturally lacks endogenous Aβ proteins
(Ewald and Li, 2010; Link, 1995), insertion of the Aβ1–40A2V gene
reproduced the homozygous state of the human pathology.
Although Link and colleagues generated various transgenic C. elegans
strains expressing Aβ1–42 in muscle or at the pan-neuronal level
(Dosanjh et al., 2010; Ewald and Li, 2010), no models constitutively ex-
pressing Aβ1–40 in neurons are currently available. Thus, to understand
whether the insertion of the mutant gene causes gene-speciﬁc disease
hallmarks, a transgenic C. elegans expressing the Aβ1–40 WT (Aβ1–40WT)
peptide was also generated.
We report here that the pathological behavior andneurotransmission
dysfunction caused by the pan-neuronal expression of the Aβ1–40WT
protein are worsened by the insertion of an A2V mutation. In addition,
Aβ1–40A2V has a greater propensity than the WT to form in vivo soluble
oligomeric species which accumulate within neuronal cells, suggesting
this was a central event in the postsynaptic damage and early disease
progression in A673V homozygous carriers (Di Fede et al., 2009).
Methods
Construction and characterization of C. elegans transgenic strains
Pan-neuronal Aβ1–40 expressionwas achieved by cloning a construct
for the expression of human Aβ1–40WT, Aβ1–42WT and A2V mutated
Aβ1–40 (Aβ1–40A2V) under the control of the aex-3 neuronal promoter.
aex-3 was subcloned into a pPD49.26 plasmid, resulting in the
pPD49.26 + aex-3 plasmid. A minigene consisting of a synthetic modi-
ﬁed signal peptide (MHKYLLALFFIFLAPAGT) and Aβ peptide was
subcloned into the pPD49.26 + aex-3 plasmid (kindly provided by
Prof. T. Tsubata). Aminigenewith the syntheticmodiﬁed signal peptide,
but without the Aβ peptide, was also subcloned into the pPD49.26 +
aex-3 plasmid and used to generate control worms (Vector). The
sequence of the constructs was conﬁrmed by DNA sequencing.
Transgenes were introduced into the MT309 multivulva C. elegans
strain (Caenorhabditis Genetics Center, CGC, University of Minnesota,
USA) by gonad microinjection of a DNA solution containing 10 ng/μl
of the Aβ construct together with 2.5 ng/μl of ttx-3::rfp and 2.5 ng/μl
of plin-15(+) as marker plasmids. Multiple extrachromosomal lines
were established based on the ﬂuorescent marker and the disappear-
ance of the multivulva phenotype. The transgenic animals maintainedthe injected DNA as an extrachromosomal element. The transmitting
lines established for this study have 60–70% meiotic stability. Thus
transgenic animals produced both transgenic and non-transgenic prog-
eny. At least three independent transmitting lines were produced for
each variant. All nematode strains were grown at 20 °C on Escherichia
coli OP50.
To check the Aβ genotype of transgenic strains, reverse transcription
was performed on RNA extracted from each transgenic line. The cDNA
fragment codifying human Aβ was ampliﬁed by PCR and sequenced
using the following primers: forward 5′-GAACATTTTCAGGAGGACC-3′
and reverse 5′-TTAGAAGTCAGAGGCACGGG-3′. Quantitative real-time
PCR was also performed. Brieﬂy, RNA was extracted using the RNeasy
Plus Universal Mini Kit (Qiagen) and its yield was measured using a
NanoDrop 2000 Spectrophotometer (Thermo Scientiﬁc). Retro-tran-
scription was carried out using SuperScript III First-Strand (Invitrogen),
according to manufacturer's instructions. Quantitative real-time PCR
was performed on 10 μl reactions containing 300 nM of primer
(CeAβF 5′-GAATTCCGACATGACTCAGG-3′ and CeAβR 5′-GCTCACGCT
ATGACAACACC-3′ for the ampliﬁcation of Aβ), 5 μl of 2× Sso Fast Eva
Green Supermix (Bio-Rad) and 7.5 ng of each cDNA. PCR included am-
pliﬁcation of peripheral myelin gene pmp-22/GAS-3 (CePmp3F: 5′-G
TTCCCGTGTTCATCACTCAT-3′ and CePmp3R: 5′-ACACCGTCGAGAAGCT
GTAGA-3′) as normalizing control. The initial denaturation step was
performed at 98 °C for 30 s and was followed by 40 cycles at 98 °C for
8 s and 60 °C for 25 s. Each reaction was carried out in triplicate using
the Viia7 System (Applied Biosystems) and the data were analyzed
using the ΔΔCT method (Livak and Schmittgen, 2001).
SELDI-TOF MS analysis
After collection,washing and centrifugation, transgenic adult worms
were resuspended in a lysis buffer (0.5 M urea, 0.5% (v/v) Triton X-100
and protease inhibitor mixture in 5 mM phosphate buffered saline
(PBS), pH 7.4) and sonicated. Adult transgenic CL2006worms, constitu-
tively expressing Aβ3–42 in their body wall muscle cells, were also used
(McColl et al., 2009). Samples were clariﬁed by centrifugation at
13,500 ×g for 10 min, after which the supernatant was collected, put
immediately in liquid nitrogen and stored at −80 °C. Worm lysates
were analyzed by an immunoproteomic assay for Aβ peptide detection,
using SELDI-TOFMS analysis (Albertini et al., 2010). Speciﬁcally, 3 μl of a
0.125 mg/mlmonoclonal antibody solution (6E10 and 4G8, Signet)was
incubated for 2 h at room temperature in a humidity chamber to allow
covalent binding to the PS20 ProteinChip Array (Bio-Rad Laboratories
Inc.). Unreacted sites were blocked for 30 min at room temperature
with 0.5 M Tris–HCl, pH 8.0, in a humidity chamber. Each spot was
washed three times with PBS containing 0.5% (v/v) Triton X-100 then
twice with PBS alone. Spots were coated with 5 μl of sample and incu-
bated overnight in a humidity chamber before being washed three
times with PBS containing 0.1% (v/v) Triton X-100, twice with PBS
alone and ﬁnally with deionized water. One microliter of α-cyano-4-
hydroxy cinnamic acid (Bio-Rad Laboratories, Inc.) was added to each
spot and mass identiﬁcation was performed using the ProteinChip
SELDI System, Enterprise Edition (Bio-Rad Laboratories Inc.). Synthetic
peptides homologous to residues 1–40 and 1–42 of Aβ, with or without
the A2V substitution (Aβ1–40WT, Aβ1–40A2V, Aβ1–42WT, Aβ1–42A2V), and to
residues 3–42 of Aβ (Aβ3–42WT)were prepared by solid-phase synthesis
and puriﬁed as described (Di Fede et al., 2009). The purity and identity
of peptides was determined by reverse-phase HPLC, amino acid
sequencing, MALDI-TOF and SELDI-TOF MS; the purity was above
95%.
Immunoprecipitation
For immunoprecipitation experiments, 2 μg of themousemonoclonal
antibody to human Aβ17–24 (4G8, Covance) and 2 μg of themousemono-
clonal antibody to humanAβ1–16 (6E10, Covance)were immunocaptured
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manufacturer's protocol (Invitrogen). Adult transgenic Vector, WT and
CL2006 worms (~5000) were collected, washed, centrifuged and frozen
in liquid-N2. Worms were homogenized using the TeSeE homogenizer
(Bio-Rad) and acid-washed glass beads (Sigma Aldrich) in 2:1 (v:w)
lysis buffer (90% acetonitrile, 1% formic acid, 9% H2O). The lysates were
centrifuged twice at 15,000 ×g for 10 min and the supernatants were ly-
ophilized, resuspended in 5 mM PBS, pH 7.4, and then neutralized with
10 M NaOH, 1:400 (v/v). Immunoprecipitation of Aβ was performed by
adding the lysate to the Dynabeads andwashingwith 200 μl of lysis buff-
er. The eluates obtained were frozen, lyophilized and resuspended in
25 μl of 50% acetonitrile in water, and used for mass spectrometry
analysis.
Mass spectrometry (MS)
MS analysis was performed on immunoprecipitated lysates by using
an HPLC–MS/MS system consisting of a 1200 series pumps and
autosampler (Agilent Technologies, CA), interfaced to anAPI 5500 triple
quadrupole mass spectrometer, equipped with a turbo ion spray source
(AB Sciex, Canada). Synthetic peptides, homologous to residues 1–40,
1–42 and 3–42 of Aβ (20 ng/μl in 50% acetonitrile in water), were
used as standards. The HPLC separation was obtained with a Jupiter
C4 300A column, 150 × 2 mm, 5 μm particle size (Phenomenex, CA),
using an elutionmixture composed of 0.1% formic acid inwater (solvent
A) and acetonitrile (solvent B). The injection volume was 5 μl and the
ﬂow rate was 200 μl/min. The elution gradient ran from 20% up to 60%
of solvent B in 10 min, then to 98% of solvent B for 5 min and re-
equilibration for 8 min at 20% of solvent B. Themobile phasewas direct-
ly introduced into the ion source, which operatedwith a turbo ion gas at
600 °C. MS analysis was performed using positive ionization and select-
ed reaction monitoring (SRM) mode, measuring the fragmentation
products of the multiple-charged protonated pseudo-molecular ions,
as shown in Supplementary Table 1. Peptidemolecular weight and pre-
cursor ions were calculated or measured as the maximum height of the
mass spectra peaks, at unit resolution. Precursor ions were+6 and+5
multiple charged ions, as originated in the electrospray ionization
source. The choice of fragmentation products for the Aβ peptides and
the optimization of source and collision energies were performed in
continuous-ﬂow mode, using synthetic Aβ1–40, Aβ1–42 and Aβ3–42 pep-
tides at 1 ng/μl of 50% acetonitrile in water (Suppl. Fig. 1).
Aβ expression in transgenic strains
Transgenic worms were collected by washing plates with M9 buffer,
transferred to tubes, centrifuged andwashed twice to eliminate bacteria.
The worm pellet was resuspended in a lysis buffer (5 mM NaCl, 5 mM
EDTA, 1 mM dithiothreitol (DTT) and protease inhibitor mixture in
25 mM Tris, pH 7.5) and homogenized using the TeSeE homogenizer
(Bio-Rad) and acid-washed glass beads (Sigma Aldrich) (Diomede
et al., 2010). For dot-blot analysis, equal amounts of proteins from
homogenized samples (3–5 μg) were spotted in triplicate onto the
same nitrocellulose membrane (Millipore), blocked with PBS, pH 7.4
containing 0.1% (v/v) Tween 20 (PBS-T), and incubated overnight with
amousemonoclonal antibody to Aβ1–40 (11A50-B10,1:500 dilution, Sig-
net, Emeryville, CA), a mouse monoclonal antibody to human Aβ17–24
(4G8, 1:500 dilution, Sigma), a mouse monoclonal antibody to Aβ
(Clone WO2, 1:1000 dilution, Millipore) or a rabbit polyclonal antibody
recognizing high-molecular-weight oligomers (A11, 1:1000 dilution,
Biosource, USA). To minimize background staining due to non-speciﬁc
membrane-binding of the antibodies, the membranes were saturated
for 1 h at room temperature by incubation with PBS-T containing 5%
(w/v) low-fat dry milk powder and 2% (w/v) bovine serum albumin
(BSA). The Aβ species in transgenic populations were identiﬁed by im-
munoblotting using Tris-Tricine gel and western blotting (Diomede
et al., 2010). Equal amounts of protein lysate (100 μg) were fractionatedby SDS-PAGE and, after blotting, were probed with WO2 (1:1000 dilu-
tion). Anti-mouse IgG peroxidase conjugate and anti-rabbit IgG peroxi-
dase conjugate (1:5000 dilution, Sigma) were used as secondary
antibodies. A 0.1% (w/v) Red Ponceau solution (Sigma Aldrich) was
used to stain blotted membranes for visualization of total proteins.
The mean volume of the Aβ -reactive spots and Red Ponceau spots
were analyzed using Progenesis SameSpots software (Nonlinear
Dynamics, UK). The data were expressed as the mean of the volume
of the immunoreactive band/volume of total Ponceau proteins ± SD.Immunoﬂuorescence
Fluorescence microscopy on whole Vector, WT and A2V worms was
performed according to Ruvkun et al. (Finney and Ruvkun, 1990;
Ruvkun and Giusto, 1989). Brieﬂy, worms were collected, rinsed and
ﬁxed in 2% paraformaldehyde solution containing 80 mM KCl, 20 mM
NaCl, 10 mM EGTA, 5 mM spermidine-HCl (Sigma Aldrich), 15 mM
sodium-piperazine-N,N′-bis[2-ethanesulfonic acid] (Sigma Aldrich),
pH 7.4, and 25% (v/v) methanol. Worms were then rinsed in 100 mM
Tris–HCl solution, pH 7.4, containing 1% (v/v) Triton X-100 and 1 mM
EDTA, and incubated for 1 h at room temperature in the same buffer
containing 1% β-mercaptoethanol. After washing, wormswere incubat-
ed for 15 min at room temperaturewith 25 mMH3BO3 solution, pH 9.2,
containing 12.5 mMNaOH and 10 mMDTT, then incubated for 15 min
at room temperaturewith 1%H2O2. After extensivewashingwith borate
buffer, worms were incubated overnight at 4 °C with 4G8 or A11 anti-
bodies (1:100 dilution). Samples were washed for 1 h at room temper-
ature with 5 mMPBS, pH 7.4, containing 1% BSA, 0.5% Triton X-100 and
1 mM EDTA, and incubated overnight at 4 °C with an anti-mouse IgG
488 goat or an anti-rabbit IgG 546 goat antibody (1:100 dilution,
Sigma). The worms were then incubated with 4′,6-diamidino-2-
phenylindole, mounted on slides for microscopy and observed with an
inverted ﬂuorescent microscope (IX-71 Olympus) equipped with a
CDD camera (F-VIEWII) for acquiring images.Immuno-electron microscopy
Individual nematodes were cut in a transverse plane with a razor
blade just below the pharyngeal terminal bulb and ﬁxed overnight in
2% paraformaldehyde and 1% glutaraldehyde in 120 mM PIPES, 50 mM
HEPES, 8 mM MgCl2 and 20 mM EGTA buffer. They were then quickly
washed in a drop of 7.5% gelatin (Sigma Aldrich), placed on a pre-
warmed slide and embedded in 15% gelatin in 0.5 ml tubes at 37 °C.
The tubes were transferred to an ice-bucket and when the gelatin had
solidiﬁed, the embedded samples were dissected into 0.5–1 mm3 blocks
and processed overnight at 4 °C with 2.3 M sucrose on a rotating wheel.
After removing the excess sucrose, the blocks were placed on holders
and immediately frozen in liquid nitrogen. Eachholderwith frozen tissue
was then mounted on the arm of a Leica EM UC6 ultramicrotome
equipped with a cryochamber (Leica EM UC6) and an antistatic device
(Diatome, Switzerland). The samples were trimmed, sectioned to
50 nm thickness, collected on formvar/carbon-coated slot copper grids
and incubated overnight with A11 antibody(1:100) at 4 °C, followed
by 10-nm colloidal gold-conjugated protein A incubation (Cell Microsco-
py Center, Utrecht, The Netherlands) for 30 min (Diomede et al., 2010).
After labeling, sections were treated with 1% glutaraldehyde, counter-
stainedwith uranyl acetate and examinedwith an Energy Filtered Trans-
mission ElectronMicroscope (EFTEM, ZEISS LIBRA® 120) equipped with
a YAG scintillator slow-scan CCD camera. The density of gold particles
labeling A11 was measured by iTem software (Olympus Soft Imaging
Solutions, Germany). Immunoreactive oligomeric inclusions in the
neuronal cytoplasm area of WT (N = 10) and A2V (N = 25) nerve
ring neurons were identiﬁed in a number of sections, ranging from 3
up to 8 in 3 nematodes for each experimental group.
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SPR studies were carried out with the ProteOn XPR36 Protein Inter-
action Array System (Bio-Rad Laboratories) (Bravman et al., 2006)
based on SPR technology. The anti-Aβ antibody 4G8 was immobilized
on three parallel chambers of the same GLC sensor chip (Bio-Rad Labo-
ratories) by standard amine coupling chemistry, as previously described
(Stravalaci et al., 2012). An irrelevant IgG was immobilized in parallel
and used as reference. After rotation of the microﬂuidic system, lysates
from transgenic WT and A2V C. elegans strains (prepared as previously
described, without protease inhibitors) were diluted to a ﬁnal protein
concentration of 0.05 μg/μl and ﬂowed over immobilized 4G8 for
3–5 min at 30 μl/ml; dissociation was measured in the following
10–15 min. The sensorgrams (time course of the SPR signal in RU)
were normalized to a baseline value of 0. The signal in the surfaces
immobilizing 4G8 was corrected by subtracting the nonspeciﬁc
response in the reference surface.Behavioral studies
To perform lifespan experiments, gravid wormswere allowed to lay
eggs for 6–8 h to produce an age-synchronized population which was
cultured at 20 °C. Once the worms reached adulthood (at reproductive
maturity), they were transferred daily to fresh NMG plates seeded
with E. coli OP50, in absence of ﬂuorodeoxyuridine, until they stopped
laying eggs. To avoid overlapping generations, worms were then trans-
ferred daily until all nematodes were dead.Wormswere scored as dead
when there was no touch-provoked movement. The ﬁrst day of adult-
hood is day 3 in survival curves.
Body bends were recorded at room temperature using a stereomi-
croscope. L3–L4 worms were picked and transferred into a well of a
96-well ELISA plate containing 100 μl of ddH2O. The number of left–
right movements in a minute was recorded. To determine the effect of
epigallocatechin gallate (EGCG) in preventing the locomotor defect
caused by Aβ expression, egg-synchronized transgenic worms were
placed at 20 °C on fresh NMG plates seeded with E. coli OP50 (100
worms/plate). After 36 h, when worms were at L3/L4 larval stage,
they were fed 50–100 μM EGCG (100 μl/plate). Body bends in liquid
were scored 24 h later. EGCG was a kind gift from INDENA (Milan,
Italy) and was freshly dissolved in water before use.
To evaluate pharyngeal pumping, individual L3–L4 worms were
placed on NMG plates seeded with OP50 E. coli, and pumping was
scored by counting the number of times the terminal bulb of the
pharynx contracted in 1 min. For lifespan, body bends and pumping
rate experiments, N2 ancestral worms (Caenorhabditis Genetics Center,
CGC, University of Minnesota, USA) were used as a reference
strain.
Aldicarb and levamisole sensitivity was evaluated on synchronized
L4-young adult worms. Nematodes (30–50/plate) were transferred to
freshly made NGM agar plates with a small spot of OP50 E. coli solution
and 1 mM aldicarb or 1 mM levamisole was added. The worms were
prodded on the nose after 30 min and for the next 2 h to determine
when they had reached complete paralysis (Mahoney et al., 2006;
Nguyen et al., 1995).Fluorescent staining of β-amyloid
Two day old transgenic worms were ﬁxed in 4% paraformaldehyde
in PBS, pH 7.4, for 24 h at 4 °C. Nematodes were stained with 1 mM
1,4-bis(3-carboxy-hydroxy-phenylethenyl)-benzene (X-34) in 10 mM
Tris, pH 8.0, for 4 h at room temperature (Diomede et al., 2010),
destained, then mounted on slides for microscopy and observed with
an inverted ﬂuorescent microscope (IX-71 Olympus); images were
acquired using a CDD camera.Statistical analysis
The data were analyzed using GraphPad Prism 4.0 software (CA,
USA) by an independent Student's t-test and one-way ANOVA and
Bonferroni's post-test analysis. A p-value b 0.05 was considered
signiﬁcant.
Results
Pan-neuronal expression of A2V-mutated Aβ1–40 induced behavioral
defects and neurotransmission impairment
We investigatedwhether the A2V substitution in Aβ resulted in pro-
tein aggregation and toxicity in vivo in a new transgenic animal model
generated using the nematode C. elegans. The human Aβ1–40 peptide
containing the recessive A2V mutation (Aβ1–40A2V) was constitutively
expressed in the nematodes' neurons, mimicking human homozygous
carriers. Amyloid formation and proteotoxicity caused by the mutated
protein was compared to that induced by the expression of Aβ1–40WT.
The molecular weight of the Aβ protein expressed in transgenic
wormswas determined using SELDI-TOFMS analysis, in which proteins
are selectively adsorbed to a chemically modiﬁed array surface prior to
the addition of an energy-absorbing matrix solution (Albertini et al.,
2010). As shown in Fig. 1, worms transfected with the empty vector
(Vector) did not express Aβ peptide, as expected. C. elegans injected
with the mutated Aβ1–40A2V construct did express the predicted
peptide, as indicated by the SELDI-TOF MS spectra, which showed a
peak with the m/z of 4360 Da (Fig. 1), consistent with the synthetic
Aβ1–40A2V peptide (Fig. 1). The injection of Aβ1–40WT construct gave no
stable lines, but the injection of the Aβ1–42 transgene resulted in the
generation of a WT stable line. Although the generated transgenic WT
strain has an Aβ1–42 genotype, as conﬁrmed by reverse transcription
of RNA and by PCR ampliﬁcation and sequencing of the cDNA fragment
coding for human Aβ, it did not express the predicted Aβ1–42
(m/z = 4515 Da) (Fig. 1). However, a major species with an m/z of
4332 Da, compatible with either Aβ1–40 or Aβ3–42 expression, was ob-
served (Fig. 1). SELDI-TOF MS analysis was then performed on lysates
from WT transgenic worms, analyzing in parallel, as controls, the
Aβ3–42 and Aβ1–40 synthetic peptides, as well as lysates from CL2006
transgenic worms expressing Aβ3–42 (McColl et al., 2009) (Fig. 1). Due
to the difference of less than 2 Da between Aβ1–40 and Aβ3–42, the ulti-
mate identity of the peptide expressed by the transgenic WT worms
could not be resolved by using SELDI-TOF MS. In addition, due to the
low levels of Aβ related to neuronal expression, western blotting was
not able to discriminate between the presence of Aβ1–40 from Aβ3–42
in the lysates from WT worms, neither after Aβ immunoprecipitation
nor precipitation of proteins with methanol (data not shown).
An original method was then developed involving the analysis of
immunoprecipitated samples by using a triple quadrupole HPLC–MS/
MS system with SRM acquisition. To this end, synthetic Aβ1–40, Aβ1–42
and Aβ3–42 peptides were characterized by positive electrospray ioniza-
tion and the optimal SRM transitions and collision energies were deter-
mined (Table S1). The most abundant precursor ions of each peptide
were found to be multiply charged ions with 6 and 5 charges. For
Aβ1–40 and Aβ3–42 peptides, the m/z values of the precursor ions were
not distinguishable at the unit resolution of the triple quadrupole in-
strument, however the two peptides had different and unique fragmen-
tation products, which made their complete discrimination possible
(Suppl. Fig. 1). An HPLC method was also set up, which allowed the
separation and identiﬁcation of the three peptides. As shown in Supple-
mentary Fig. 2, no speciﬁc peaks corresponding to the Aβ peptideswere
observed in worms transfected with the empty vector (Vector). Lysates
from WT and CL2006 transgenic worms were then analyzed; the re-
corded chromatograms are shown in Fig. 2. Only peaks corresponding
to the retention time of Aβ3–42 were detected in lysate from CL2006
nematodes, as expected. In lysate from WT worms, no speciﬁc peaks
Fig. 1. Aβ1–40A2V expression in transgenic C. elegans. An immunoproteomic assay using SELDI-TOF MS was performed on lysates from the transgenic C. elegans strains expressing: empty
vector (C. elegans Vector), AβWT (C. elegans WT) or Aβ1–40A2V (C. elegans A2V). Aβ1–40WT, Aβ1–40A2V, Aβ1–42WT, Aβ1–42A2V and Aβ3–42WT synthetic peptides were loaded and analyzed as
reference standards. Lysates from transgenic CL2006 worms were also analyzed (CL2006).
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to the SELDI-TOF spectra whereas peaks corresponding to the reten-
tion time of Aβ1–40 were observed (Fig. 2). These data clearly demon-
strate that transgenic C. elegans WT strain only express the Aβ1–40
peptide.
The expression level of Aβ1–40 peptide in WT- and A2V-expressing
transgenic wormswasmeasured by quantifyingmRNA. The two strains
had similar relative quantities of AβmRNA, normalized to worm pmp-
22/GAS-3 content (10.3 ± 1 vs. 15.0 ± 3.8 for WT and A2V worms,
respectively).
The Aβ species expressed in transgenic strains were also character-
ized by dot blotting using antibodies speciﬁc to Aβ1–40 (11A50-B10)
or the anti-Aβ monoclonal antibody 4G8, and using as control the
Aβ1–40 synthetic peptide as control. Lysates from WT and A2V strains
were immunoreactive for both antibodies (Fig. 3A). The immunoreac-
tivity of 11A50-B10 was quantiﬁed and the data obtained indicated
that A2V and WT strains expressed comparable Aβ1–40 protein levels
(p = 0.159, WT vs. A2V, Student's t-test) (Fig. 3B). Similar data were
obtained using the anti-Aβ monoclonal antibody 4G8 (p = 0.537, WT
vs. A2V, Student's t-test) (Fig. 3C).The lysates of the different transgenic C. elegans strains were then
analyzed via western blot using the anti-Aβ antibody WO2. The total
immunoreactivity of WO2, indicative of the total Aβ, and the immuno-
reactivity speciﬁcally related to the 56 kDa and 20 kDa bands were
quantiﬁed and normalized to the protein content. As shown in Supple-
mentary Fig. 3, a similar total Aβ level was produced by WT and A2V
worms, whereas a signiﬁcant increase in the 20 kDa Aβ oligomeric
species and a decrease in the band at 56 kDa were observed in lysates
from A2V worms. The absence of monomeric Aβ in the western
blot of WT and A2V nematodes can be attributed to the low Aβ levels
following the neuronal expression.
Immunoﬂuorescence studies showed a 4G8-positive signal in ani-
mals expressing the WT or mutated Aβ1–40 starting from the larval
stage L2 (Suppl. Fig. 4). At this stage and in 2-day-old worms ﬂuores-
cence was localized in the nerve ring of the head region, in the ventral
cord and lateral body wall neurons, and in the tail ganglia, in both
WT and mutated worms (Fig. 4). There was no 4G8-speciﬁc signal in
worms transfected with the empty vector (Figs. 4E–F).
We then evaluated whether the constitutive expression of WT or
A2V led to the neuronal accumulation of ﬁbrillar Aβ deposits. To this
Fig. 2.HPLC-selected reactionmonitoring (SRM) chromatograms relative to the analysis of Aβ in transgenic C. elegans strains. Synthetic Aβ3–42, Aβ1–40 and Aβ1–42 peptideswere dissolved
at 20 ng/μl in 50% acetonitrile inwater and analyzed. The retention time of the peaks for synthetic Aβ3–42 (6.01 min), Aβ1–40 (5.80 min) and Aβ1–42 (6.09 min)were identiﬁed and labeled.
In lysate from transgenic C. elegansWT, only peaks corresponding to the retention time of Aβ1–40 (5.77 min)were detected, whereas no speciﬁc peaks corresponding to the retention time
of Aβ3–42 and Aβ1–42 (red arrows) were observed. In lysate from CL2006 worms, only peaks corresponding to the retention time of Aβ3–42 were observed (5.98 min). Red arrows indicate
the retention times at which Aβ1–40 and Aβ1–42 peaks were expected. All chromatograms were obtained from the injection volume of 5 μl; instrumental parameters are reported in the
Methods section.
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which speciﬁcally recognizes Aβ ﬁbrillar aggregates but not oligomers
(Diomede et al., 2010; Link et al., 2001). The co-localization of the
TTX-3::RFP and X-34 ﬂuorescence in the heads of the A2V nematodes
indicated that the dye can enter the neurons (Suppl. Fig. 6). However,
no X-34 positive spots were observed in neurons of either WT or A2V
nematodes (Suppl. Fig. 5), indicating that the expression of Aβ1–40 in
these transgenic worms did not result in amyloid deposition. This
might be due to the low neuronal peptide concentration.
The effect of WT and mutated protein expression on overall nema-
tode survival was also investigated. The insertion of the transgene
alone, without the Aβ construct, did not affect the nematodes' survival
(median survival was 10 and 9 days for N2 and Vector worms, respec-
tively). Aβ1–40WT expression signiﬁcantly reduced the lifespan of trans-
genic worms by 22%, compared to nematodes injected with the empty
vector (Fig. 5A, median survival respectively: 9 and 7 days for Vector
and WT, p = 0.009, log-rank analysis). Insertion of the A2V mutated
gene shortened survival by 44% (median survival 5 days for A2V,
p = 0.0004 vs. Vector, log-rank analysis) (Fig. 5A). The median lifespan
ofworms expressing theA2Vmutated proteinwas 29% shorter thanWT
(p = 0.0005, log-rank analysis).
The coordination andmotility of C. elegans is controlled bynumerous
neurons innervating body wall muscle cells; misfolded proteins can
cause their dysfunction (Dosanjh et al., 2010; Sengupta and Samuel,
2009; Wang et al., 2009). The motility of Aβ-expressing worms was
evaluated by counting body bends to quantify their locomotion in
liquid. Worms transfected with the empty vector had a motility similarto ancestral N2 animals (Vector, 191.2 ± 6 body bends/min; N2,
186.8 ± 10 body bends/min, N = 50worms/group) indicating that in-
sertion of only the transgene, without the Aβ construct, did not affect
neuronal function. Body bends were signiﬁcantly decreased by expres-
sion of the Aβ peptide (135.5 ± 7 and 164.6 ± 5 bends/min for A2V
and WT, respectively, p b 0.01 one-way ANOVA vs. Vector, N = 50
worms/group) (Fig. 5B). The loss of motility was greater in A2V
mutants, which showed signiﬁcantly fewer body bends than WT
worms (Fig. 5B).
We then investigated whether the expression of Aβ1–40 affected pha-
ryngeal contraction rates, which are controlled by neurons in the pharyn-
geal nervous system. The pharyngeal pumping rate in worms transfected
with the empty vector was similar to N2 worms (205.9 ± 3.1 and
215.4 ± 5.1 pumps/min, respectively, N = 30 worms/group) whereas
nematodes expressing Aβ1–40WT and Aβ1–40A2V showed signiﬁcantly
lower rates (−11% and−21% respectively vs. Vector) (Fig. 5C). The ex-
pression of the mutated protein caused more defective pumping than
the expression of Aβ1–40WT (182.5 ± 2 pumps/min of WT vs. 162.4 ± 5
pumps/min of A2V, p b 0.01 one-way ANOVA, N = 30 worms/group)
(Fig. 5C).
Locomotion in nematodes, like pharyngeal pumping, is controlled by
acetylcholine receptors which mediate synaptic functions (Mahoney
et al., 2006). We explored whether the neuronal expression of Aβ1–40,
with or without the A2V mutation, affected cholinergic transmission
by recording the paralyzing effect of a cholinergic agonist (levamisole)
and an acetylcholinesterase inhibitor (aldicarb). Levamisole induces
muscle hypercontraction and paralysis, by activating postsynaptic,
Fig. 4. Location of Aβ1–40 in transgenic C. elegans strains. Representative images obtained in bright ﬁeld (A, C, E) and by immunoﬂuorescence analyses (B, D, F) of Aβ1–40WT (A, B) and
Aβ1–40A2V-expressing worms (C, D). The 4G8 antibody immunostaining of worms expressing empty vector is reported in panel F. All animals are 2-day-old adults. A 4G8 positive signal
(green) was observed in the head region (in the nerve ring area), ventral cord and lateral body wall neurons and in the tail ganglia (white arrows). Scale bar, 50 μm.
Fig. 3. Aβ species in transgenic C. elegans. (A) Representative dot blot of Aβ1–40(11A50-B10) and total Aβ (4G8) inWT and A2V transgenic worms. Equal amounts of proteins fromworm
lysates (5 μg)were spotted in triplicate. Nematodes injectedwith the empty vector (Vector)were used as control strain. Aβ1–40 synthetic peptide (2 μg)was spotted as an internal control.
Total proteins on the blotted membranes were stained using a 0.1% Red Ponceau solution and were used as housekeeping control. The mean volume of the Aβ-reactive and Red Ponceau
spotswas analyzed using Progenesis SameSpots software (NonlinearDynamics, UK). Immunoreactivity of (B) 11A50-B10 and (C) 4G8 from three independent experiments (N = 9)were
expressed as the mean of the volume of the immunoreactive band / volume of total Ponceau proteins ± SD.
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Fig. 5. Survival and behavioral phenotype of transgenic C. elegans. (A) Kaplan–Meier survival curves of hermaphrodite adult worms expressing Aβ1–40WT (WT, squares) and Aβ1–40A2V (A2V,
triangles). Vector (circles) and transgenic animalswereplaced on plates seededwithOP50 starting fromL4, cultured at 20 °C and transferred to fresh plates on consecutive days. Survivalwas
scored every day and is expressed as a percentage. Plots are representative of three independent experiments (N = 100). WT expression signiﬁcantly reduced the lifespan of transgenic
worms by 22% compared to nematodes injected with the empty vector (median survival: 9 and 7 days for empty vector and WT respectively, p = 0.009, log-rank analysis). Insertion of
the A2V mutated gene further shortened survival by 44% (median survival is 5 days for A2V, p = 0.0004 vs. empty vector, log-rank analysis). The median lifespan of worms expressing
theA2Vmutated proteinwas 29% shorter thanWT (p = 0.0005, log-rank). (B) Locomotor defects were scored in L3–L4 transgenic worms bymeasuring the number of body bends in liquid.
At least three independent assays were performed (N = 50 animals in each group). Data are expressed as the mean number of body bends/min ± SD. (C) Pharyngeal pumping rate was
scored in L3–L4 transgenic worms by determining the number of pumps/min. At least three independent assays were performed (N = 30 animals per group) and the data are expressed
as the mean pumps/min ± SD. **p b 0.01 vs. Vector, °°p b 0.01 vs. WT, by one-way ANOVA and Bonferroni's post-test analysis. (D) Levamisole sensitivity of transgenic strains. WT and
A2V synchronized L4-young adult transgenic worms were exposed for different times (0–90 min) to 1 mM levamisole and the animals not moving were scored as paralyzed. At each
time point, the percentage of paralyzed worms was calculated. At least three independent assays were performed. Data are the mean ± SD (N = 30). *p b 0.01 vs. Vector and °p b 0.01
vs. WT at each time point, by one-way ANOVA and Bonferroni's post-test analysis. (E) Effect of epigallocatechin gallate (EGCG) on Aβ-induced locomotory defect in transgenic C. elegans
strains. Egg-synchronized controlworms (Vector),WT andA2Vnematodeswereplaced at 20 °C on freshNMGplates seededwithOP50.Whenwormswere at theL3–L4 larval stage, animals
were fed 50 μM EGCG (100 μl/plate). Body bends in liquid were scored 24 h after. At least three independent assays were performed. Data are the mean of the number of body bends/
min ± SD. **p b 0.01 vs. Vector, p b 0.01 vs.WT, °°p b 0.01 vs. the respective untreated group, according to one-way ANOVA (N = 40 animals for each group).
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Aβ-expressing worms were signiﬁcantly more resistant to levamisole
than the corresponding animals transfected with the empty vector
(Fig. 5D). Those expressing Aβ1–40A2V were more resistant thanWT, in-
dicating that the mutated protein caused a worse impairment in post-
synaptic function. The expression of WT or mutated Aβ1–40 alsoresulted in resistance to aldicarb-induced paralysis, an indication of a
synaptic transmission defect. However, no signiﬁcant differences were
observed between transgenic WT and A2V animals (Suppl. Fig. 6).
The consistency of these new transgenic C. elegans strains in recapit-
ulating important clues to the amyloidosis was also investigated by
studying the response to EGCG, a polyphenolic green tea constituent.
529L. Diomede et al. / Neurobiology of Disease 62 (2014) 521–532This is a prototypical inhibitor of oligomerization (Stravalaci et al., 2012),
emerging as an anti-amyloidogenic compound, which counteracts ag-
gregation and ﬁbrillogenesis of various amyloidogenic proteins, includ-
ing Aβ (Bieschke et al., 2010; Ehrnhoefer et al., 2008). It is currently
under investigation in a Phase II–III Clinical Trials (ClinicalTrials.gov
Identiﬁer: NCT00951834).
Worms were fed for 24 h with either vehicle or 50–100 μM EGCG,
and thebody bendswere scored. EGCGdid not affect themotility of Vec-
tor worms at any of the doses tested (192.0 ± 3 and 193.2 ± 3 body
bends/min for Vector fed vehicle and 100 μM EGCG, respectively,
N = 50worms/group). As shown in Fig. 5E, 50 μMEGCG completely re-
versed the reduction in body bends caused byAβ expression in bothWT
and A2V worms. Similar data were obtained by feeding worms with
100 μM EGCG (data not shown). This protective effect was paralleled
by the ability of EGCG to reduce the oligomer levels in WT and A2V
worms (Suppl. Fig. 7).Aβ1–40A2V expression resulted in higher production of oligomeric species
Introduction of the A2V substitution in the synthetic Aβ1–40 peptide
enhances its in vitro aggregation and ﬁbrillogenic properties (Di Fede
et al., 2009), as well as its propensity to form oligomers (Stravalaci et al.,
2012). To investigate whether the A2V mutation modiﬁes the AβFig. 6. Aβ oligomers in transgenic C. elegans strains. (A) Representative dot blots of Aβ oligomer
worms and (C) the A11-immunoreactivity as a function of the total Aβ quantiﬁed from
A11-immunoreactive bands/volume ofWO2-immunoreactive bands ± SD from three indepen
of Vector,WT and A2V transgenic worms after immunostainingwith A11 antibody. All animals
4′,6-diamino-2-phenylidole (blue). In A2Vworms, oligomers (green arrows) were associatedw
whereas in WT animals the A11-positive signal was only in the head. Scale bar, 50 μm.assembly in vivo, lysates from adult transgenic C. elegans were analyzed
using different experimental approaches. First, lysates were analyzed by
dot blotting, using the anti-oligomer antibody A11. As shown in Fig. 6A,
no immunoreactivity was observed in worms injected with the vector;
however the expression of Aβ1–40WTwas accompanied by the appearance
of A11-positive signal which was stronger in A2V mutants. In agreement
with the data reported in Fig. 3 and in Supplementary Fig. 3, the total
amount of Aβ, quantiﬁed from the dot blot with the WO2 antibody
(Fig. 6B), was similar in the two transgenic strains. The A11-
immunoreactivity was then normalized against WO2-immunoreactivity
and the results obtained indicated that the presence of the A2Vmutation
caused a three-fold increase in the proportion of A11-stained oligomers
(p b 0.01, Student's t-test, N = 9) (Fig. 6C). Such a feature is consistent
with the increase in the 20 kDa band reported in Supplementary Fig. 3
and with the well-established in vitro propensity of mutated Aβ1–40A2V
to misfold and self-aggregate (Di Fede et al., 2009; Stravalaci et al.,
2012).
Immunoﬂuorescence studies with the A11 antibody were then
carried out to look for differences in oligomer deposition between trans-
genic WT and A2V worms (Fig. 6D). WT nematodes showed a speciﬁc
ﬂuorescence signal only in neurons in the head, lower than that found
in animals expressing the mutated peptide. The latter also showed in
the ventral cord and lateral body wall (Fig. 6D). No A11-positive stain-
ing was observed in Vector nematodes (Fig. 6D).s (A11) in transgenic worms. (B) Representative dot blots of total Aβ (WO2) in transgenic
the dot blot obtained using the WO2 antibody. Data are the mean of the volume of
dent experiments (N = 9). **p b 0.01 vs.WT (Student's t-test). (D) Representative images
are 2-day-old adults. Arrows indicate the A11-positive signal (red). DNAwas probed using
ith the nerve ring in the head region, in the ventral and lateral body regions, and in the tail,
Fig. 7. Immuno-electron microscopy of transgenic C. elegans strains. Transmission electron microscopy representative images of the nerve ring neurons in the head region ofWT (A) and
A2V (B) 4-day-old adult transgenic C. elegans. A11-positive oligomers (arrows), indicated by the interactionwith the 10 nmgold-conjugated protein A, accumulated in the cytosol of neu-
rons. Nu: nucleus, Mit: mitochondria, Scale bar 200 nm. (C) The quantiﬁcation of A11 immunolabeling inWT (N = 10) and A2V (N = 25) nerve ring neuronswas expressed as the num-
ber of neuronal gold particles divided by cytoplasmic area (*p b 0.001 vs.WT, Student's t-test).
Fig. 8.Aβ1–40 oligomers in transgenic C. elegans strains recognized by SPR-based immuno-
assay. Lysates from transgenic worms expressing Aβ1–40WT (WT) or Aβ1–40A2V (A2V)were
ﬂowed for 3 min (bar) onto a sensor chip on which we previously immobilized 4G8. Ly-
sates from worms transfected with the empty vector were used as control (Vector). The
three-min association phase was followed by 11 min of dissociation. The ﬁgure shown
the obtained sensorgrams, i.e. the time course of the SPR signal expressed in resonance
units (RU), obtained in a single experimental session. Very similar results were found in
four independent sessions, with new sensor-chips and ex novo preparations of worm
lysate.
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A11 antibody to see whether oligomers localized in neurons (Figs. 7A–
B). Quantiﬁcation of A11-binding with a gold-labeled secondary
antibody indicated a 5.4 fold signiﬁcant increase (p b 0.001, Student's
t-test) in immunoreactive oligomeric inclusions in the cytoplasm of
A2V nerve ring neurons (10.94 ± 2.00 gold particles/μm2) compared
to WT worms (2.02 ± 0.35 gold particles/μm2) (Fig. 7C). In addition,
there were some morphological abnormalities in neurons of Aβ1–40A2V
expressing worms, including swollen and enlarged mitochondria
(Fig. 7B). No immunoreactive signalwas observed inworms transfected
with the empty vector (data not shown).
Finally, we used a novel immunoassay based on surface plasmon
resonance (SPR), which speciﬁcally recognizes biologically active Aβ
oligomers (Stravalaci et al., 2012), Themethod exploits the fact that sol-
uble oligomers bind to chip-immobilized 4G8 in a pseudo-irreversible
manner (very slowdissociation rates, likely due tomultivalent binding),
whereasmonomers bindwith signiﬁcantly faster dissociation rates, and
higher-order aggregates are not detectable.We note that the possibility
to use 4G8 to discriminate between different Aβ species, and to selec-
tively detect soluble oligomers, is due to the speciﬁc features of SPR,
e.g. the fact that it measures the binding events in real time on a time
scale of seconds. This assay has been already applied to detect the
A11-positive Aβ1–42 oligomers present in lysates from transgenic
worms expressing Aβ1–42 (Stravalaci et al., 2012). As shown in Fig. 8,
the analysis of lysates from A2V nematodes resulted in a much higher
SPR signal than that observed in WT, indicating a greater amount of
4G8-binding species. As expected, no signal was observed with lysatesfrom worms transfected with the Vector (Fig. 8). Importantly, most of
the SPR signal observed with WT lysates was due to quickly-
dissociating species (i.e. monomers), whereas most of the binding
observed with mutant lysates was due to slowly-dissociating species
(i.e. oligomers). These SPR data indicate that the lysates from
531L. Diomede et al. / Neurobiology of Disease 62 (2014) 521–532Aβ1–40A2V-expressing worms contained more oligomeric species than
lysates from WT worms, in agreement with the data obtained via dot-
blotting, western blotting, immunoﬂuorescence and immune-electron
microscopy analyses.
Discussion
It has been previously shown that the occurrence of A673Vmutation
in the APP gene only results in an early-onset dementia in humans in
the homozygous state (Di Fede et al., 2012). In vitro studies also showed
that the corresponding A2V mutation in the Aβ peptide enhances its
aggregation and ﬁbrillogenic properties (Di Fede et al., 2009, 2012). To
address speciﬁc questions on the proteotoxicity of the A2V protein
variant, speciﬁcally the correlation of its aggregation state with the dys-
functional phenotypes underlying the neurodegenerative pathology,
we have generated a new transgenic C. elegans strain expressing
human Aβ1–40 which carries the recessive A2V mutation in its neurons.
Since this nematode naturally lacks endogenous Aβ proteins, introduc-
tion of the mutated gene recapitulates the human homozygous state of
the disease. A transgenic C. elegans strain producing Aβ1–40WT in neu-
rons was also created. To deﬁnitively demonstrate that WT strain
worms produce Aβ1–40, but not Aβ1–42 and Aβ3–42, we developed an in-
novative and highly sensitivemethod involving the use of HPLC–MS/MS
which, based on the separation of different and unique fragmentation
products, completely discriminates among the three Aβ peptides. An
N-terminal truncation of Aβ was already reported in the transgenic
CL2006 C. elegans strain created with an Aβ1–42 construct but actually
expressing Aβ3–42 peptide (McColl et al., 2009). This represents the
ﬁrst description of a C-terminus trimming of Aβ in C. elegans andwe hy-
pothesized that it was due to a C-terminal truncation during protein
processing, e.g. by neutral dipeptidases or carboxypeptidases. The
possibility of Aβ truncation or modiﬁcations must therefore be taken
into account when new transgenic strains are generated, and an
accurate protein analysis must be conducted.
Nematodes expressing the mutant gene had a shorter lifespan than
WT, indicating that Aβ1–40A2V has a greater in vivo toxicity than
Aβ1–40WT. Accordingly, the behaviors of transgenic mutated worms
were speciﬁcally altered by the A2V substitution in the Aβ1–40 peptide.
In particular, we demonstrated a worse impairment of locomotor activ-
ity and pharyngeal pumping rates in nematodes expressing Aβ1–40A2V
rather than Aβ1–40WT.
Although extracellular aggregates are thought to play a primary role in
the disruption of synaptic plasticity, numerous studies indicated that
intraneuronal accumulation of oligomeric non-ﬁbrillar Aβmay contribute
to early postsynaptic dysfunction and neurodegeneration (Capetillo-
Zarate et al., 2012; Gimenez-Llort et al., 2007; Wirths and Bayer, 2012).
In both transgenic WT and A2V worms, Aβ1–40 was expressed
intraneuronally, due to the presence of the signal peptide sequence in
the construct. Thus the speciﬁc behavioral impairment was related to
the intracellular toxicity of Aβ assemblies. Both WT and mutated strains
showed resistance to aldicarb, indicating that the intracellular Aβ1–40 as-
sembly affects cholinergic neurotransmission. The observation that the
expression of Aβ1–40, in particular in the mutated form, makes the
worms more resistant to the paralysis induced by levamisole, a potent
cholinergic agonist, indicates postsynaptic defects involving alterations
to acetylcholine receptors. Synaptic dysfunctions arising from the neuro-
nal expression of Aβ1–42 in C. elegans had already been reported (Dosanjh
et al., 2010).
Previous in vitro data using the synthetic peptides indicated that the
A2V mutation boosts the formation of Aβ1–40 transient oligomeric spe-
cies, as recognized by an SPR-based immunoassay using 4G8 antibody
(Stravalaci et al., 2012). The data now obtained in transgenic C. elegans
provide an in vivo conﬁrmation that Aβ1–40A2V has a higher propensity
to form oligomers than Aβ1–40WT. This was demonstrated by dot blot,
westernblot, immunohistochemistry and immune-electronmicroscopy
studies with the anti-oligomer antibody A11, and by SPR immunoassay.We suggest that the worsened phenotype observed in the A2V worms,
including neuronal dysfunction at postsynaptic level, is associated with
the higher propensity of Aβ1–40A2V to form oligomeric assemblies.
The description of the A673V mutation in the APP gene led us to
re-consider the role of the Aβ amino-terminal sequence in Aβ
misfolding and toxic properties (Di Fede et al., 2012). The present data
further conﬁrm that this domain is involved in the assembly of Aβ1–40
into oligomeric conformations with proteotoxic and neurotoxic activity
in vivo.
Despite the differences between nematodes and vertebrates, this
new transgenic C. elegans model, in which the defect is gene-speciﬁc
and disease-relevant, opens new avenues for in vivo study of the rela-
tion between themolecular assemblies generated byN-terminalmutat-
ed Aβ and synaptic dysfunctions. Moreover, these new transgenic
C. elegans strains represent convenient and attractive tools for an
in vivo screening of compounds interfering with oligomer formation
and/or effects, as shown in the present study with EGCG.Abbreviations
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